These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 26578234)

  • 21. The effect of zoledronic acid and osteoprotegerin on growth of human lung cancer in the tibias of nude mice.
    Tannehill-Gregg SH; Levine AL; Nadella MV; Iguchi H; Rosol TJ
    Clin Exp Metastasis; 2006; 23(1):19-31. PubMed ID: 16715352
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis.
    Daubiné F; Le Gall C; Gasser J; Green J; Clézardin P
    J Natl Cancer Inst; 2007 Feb; 99(4):322-30. PubMed ID: 17312309
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Zoledronic acid inhibits both the osteolytic and osteoblastic components of osteosarcoma lesions in a mouse model.
    Labrinidis A; Hay S; Liapis V; Ponomarev V; Findlay DM; Evdokiou A
    Clin Cancer Res; 2009 May; 15(10):3451-61. PubMed ID: 19401351
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Antitumor properties of the bisphosphonate zoledronate and potential therapeutic implications in the clinic].
    Clézardin P
    Bull Cancer; 2010 Aug; 97(8):937-49. PubMed ID: 20595092
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Zoledronic acid - a multiplicity of anti-cancer action.
    Yuasa T; Kimura S; Ashihara E; Habuchi T; Maekawa T
    Curr Med Chem; 2007; 14(20):2126-35. PubMed ID: 17691952
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Is retention of zoledronic acid onto bone different in multiple myeloma and breast cancer patients with bone metastasis?
    Søe K; Plesner T; Jakobsen EH; Hansen CT; Jørgensen HB; Delaissé JM
    J Bone Miner Res; 2013 Aug; 28(8):1738-50. PubMed ID: 23427025
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Pharmacological Profile of a Novel Highly Potent Bisphosphonate, OX14 (1-Fluoro-2-(Imidazo-[1,2-α]Pyridin-3-yl)-Ethyl-Bisphosphonate).
    Lawson MA; Ebetino FH; Mazur A; Chantry AD; Paton-Hough J; Evans HR; Lath D; Tsoumpra MK; Lundy MW; Dobson RL; Quijano M; Kwaasi AA; Dunford JE; Duan X; Triffitt JT; Jeans G; Russell RGG
    J Bone Miner Res; 2017 Sep; 32(9):1860-1869. PubMed ID: 28337806
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Macrophages as potential targets for zoledronic acid outside the skeleton-evidence from in vitro and in vivo models.
    Rogers TL; Wind N; Hughes R; Nutter F; Brown HK; Vasiliadou I; Ottewell PD; Holen I
    Cell Oncol (Dordr); 2013 Dec; 36(6):505-14. PubMed ID: 24177992
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bisphosphonate anticancer activity in prostate cancer and other genitourinary cancers.
    Saad F; Mulders P
    Anticancer Agents Med Chem; 2012 Feb; 12(2):129-36. PubMed ID: 21864229
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combined effects of bisphosphonate and radiation on osteosarcoma cells.
    Ryu K; Murata H; Koto K; Horie N; Matsui T; Nishigaki Y; Sakabe T; Takeshita H; Itoi M; Kimura S; Ashihara E; Maekawa T; Fushiki S; Kubo T
    Anticancer Res; 2010 Jul; 30(7):2713-20. PubMed ID: 20683003
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Probenecid as a sensitizer of bisphosphonate-mediated effects in breast cancer cells.
    Ebert R; Meissner-Weigl J; Zeck S; Määttä J; Auriola S; Coimbra de Sousa S; Mentrup B; Graser S; Rachner TD; Hofbauer LC; Jakob F
    Mol Cancer; 2014 Dec; 13():265. PubMed ID: 25496233
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Regression of a primary pulmonary adenocarcinoma after zoledronic acid monotherapy.
    Nagao S; Hattori N; Fujitaka K; Iwamoto H; Ohshimo S; Kanehara M; Ishikawa N; Haruta Y; Murai H; Kohno N
    Hiroshima J Med Sci; 2011 Mar; 60(1):7-9. PubMed ID: 21675041
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of a cathepsin K inhibitor in a preclinical model for prevention and treatment of breast cancer bone metastasis.
    Duong LT; Wesolowski GA; Leung P; Oballa R; Pickarski M
    Mol Cancer Ther; 2014 Dec; 13(12):2898-909. PubMed ID: 25249554
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of bisphosphonate zoledronic acid in hepatocellular carcinoma, depending on mevalonate pathway.
    Honda Y; Takahashi S; Zhang Y; Ono A; Murakami E; Shi N; Kawaoka T; Miki D; Tsuge M; Hiraga N; Abe H; Ochi H; Imamura M; Aikata H; Chayama K
    J Gastroenterol Hepatol; 2015 Mar; 30(3):619-27. PubMed ID: 25167891
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The activity of zoledronic Acid on neuroblastoma bone metastasis involves inhibition of osteoclasts and tumor cell survival and proliferation.
    Peng H; Sohara Y; Moats RA; Nelson MD; Groshen SG; Ye W; Reynolds CP; DeClerck YA
    Cancer Res; 2007 Oct; 67(19):9346-55. PubMed ID: 17909043
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fluorescence-guided surgery of prostate cancer bone metastasis.
    Miwa S; Matsumoto Y; Hiroshima Y; Yano S; Uehara F; Yamamoto M; Zhang Y; Kimura H; Hayashi K; Yamamoto N; Bouvet M; Sugimoto N; Tsuchiya H; Hoffman RM
    J Surg Res; 2014 Nov; 192(1):124-33. PubMed ID: 24972740
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Can the microRNA expression profile help to identify novel targets for zoledronic acid in breast cancer?
    Fanale D; Amodeo V; Bazan V; Insalaco L; Incorvaia L; Barraco N; Castiglia M; Rizzo S; Santini D; Giordano A; Castorina S; Russo A
    Oncotarget; 2016 May; 7(20):29321-32. PubMed ID: 27081088
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibitory effects of a new bisphosphonate, minodronate, on proliferation and invasion of a variety of malignant bone tumor cells.
    Kubo T; Shimose S; Matsuo T; Tanaka K; Yasunaga Y; Sakai A; Ochi M
    J Orthop Res; 2006 Jun; 24(6):1138-44. PubMed ID: 16705696
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effects of bisphosphonate on the remodeling of different irregular bones in mice.
    Su J; Feng M; Han W; Zhao H
    J Oral Pathol Med; 2015 Sep; 44(8):638-48. PubMed ID: 25370709
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Synergistic effect of bisphosphonate and docetaxel on the growth of bone metastasis in an animal model of established metastatic bone disease.
    van Beek ER; Lowik CW; van Wijngaarden J; Ebetino FH; Papapoulos SE
    Breast Cancer Res Treat; 2009 Nov; 118(2):307-13. PubMed ID: 18989771
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.